⌘K
t
Nuformix plc announced that its Executive Director, Dr Dan Gooding, will host an online Q&A session for existing and prospective shareholders. The session is scheduled for 5:30 p.m. GMT on Tuesday, 13 June 2023. Participants can submit questions in advance or during the event.
| Date | 2 Jun 2023 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 4197B |
REACH
2 June 2023
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Investor Online Q&A
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company's Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023. This session is open to all existing and prospective shareholders. Those who wish to attend should register via the following link where they will be provided with access details:
https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg
Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director
|
Via IFC Advisory
|
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
John Howes / Bob Pountney (Corporate Broking) |
+44 (0) 20 3650 3652
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.